Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
152 hedge funds and large institutions have $819M invested in Merrimack Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 47 reducing their positions, and 14 closing their positions.
87% more call options, than puts
Call options by funds: $3.47M | Put options by funds: $1.85M
71% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 14
25% more capital invested
Capital invested by funds: $657M → $819M (+$163M)
6% more funds holding
Funds holding: 143 → 152 (+9)
4% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$31.4M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
+$23.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.9M |
| 5 |
TA
Teachers Advisors
New York
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.79M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.15M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$4.87M |
| 4 |
Renaissance Technologies
New York
|
-$2.89M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$2.34M |
MACK Hedge Fund Activity: Q1 2015 in Review
152 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2015, worth a combined $819M — up 25% from $657M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new MACK positions and 14 closed out — a net gain of 10 holders — while 49 added to existing stakes and 47 trimmed.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $31.4M. The largest seller was Millennium Management, cutting an estimated $9.79M.
- 152 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2015, up from 143 in Q4 2014.
- Funds reported $819M of Merrimack Pharmaceuticals, Inc. stock for Q1 2015, up 25% quarter-over-quarter.
- 24 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2015 and 14 closed out, a net change of +10 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2015 was Westfield Capital Management, an estimated $31.4M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2015 was Millennium Management, an estimated $9.79M sold.
Based on aggregated 13F filings for Q1 2015.